Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like Celltrion Files Two Additional Petitions for PTO Review of Genentech’s Herceptin Patents May 12, 2017 Petition Calls on FDA to Set Timeline for Designation Appeals Process March 9, 2017 AI-Powered Medical Devices — Regulating Products That Continually Change April 7, 2023
Celltrion Files Two Additional Petitions for PTO Review of Genentech’s Herceptin Patents May 12, 2017